Key result
The prothrombin G20210A mutation increased the risk of pregnancy complications compared to wild-type controls.
Why the study?
To study the association between high prothrombin (Factor II) activity in blood plasma in G20210A mutation carriers and the development of great obstetrical syndromes.
Does the prothrombin G20210A mutation and associated high Factor II activity increase the risk of pregnancy complications such as preeclampsia and fetal growth retardation?
Cohort (n=290)
No
Does the prothrombin G20210A mutation and associated high Factor II activity increase the risk of pregnancy complications such as preeclampsia and fetal growth retardation?
High Factor II activity in pregnant women with the prothrombin G20210A mutation is strongly associated with and predictive of severe obstetrical complications like preeclampsia.
Answers are grounded in this paper and cite their sources.
May support preconception Factor II testing for risk stratification in mutation carriers; hypothesis-generating and requires prospective validation before practice change.
Objective to study the association between high activity of Factor II (prothrombin) in blood plasma with G20210A mutation and the development of great obstetrical syndromes. Material and methods A prospective clinical cohort study was conducted on 290 pregnant women (average age 31.7±4.7 years old). The main group was made up of 140 G20210A patients, while the control group comprised 150 women with the wild G20210G type. The aim was to evaluate the activity of Factor II in the venous blood plasma during the stages of pregnancy with regard to trophoblast invasion waves. As per results, association analysis of Factor II activity value and gestational complications was carried out. Results In the control group, the median (Me) of Factor II activity ranged from 108% (preconception period) to 144% (pregnancy) [95% CI 130-150]. In patients with the GA type, the value was significantly higher in related periods, ranging from 149% to 181% [95% CI 142-195], p<0.0001. With Factor II activity ranging from 148.5% to 180.6%, pregnancies in the main group had no complications. Higher levels of Factor II activity were associated with the development of early and/or severe preeclampsia (PE) and fetal growth retardation (FGR). Conclusion The data obtained regarding Factor II activity in blood plasma, juxtaposed with the development of great obstetrical syndromes, allow to assume that manifestation of G20210A in early and/or severe PE and FGR is associated with this coagulation factor's level of activity. Threshold value of the Factor II activity with G20210A mutation, allowing to predict the development of PE, comprised 171.0% at the preconception stage (AUC – 0.86; p<0.0001) and within 7-8 weeks of gestation it was 181.3% (AUC – 0.84; p<0.0001).
No takes yet. Share an insight, caveat, or question.
Nikolaeva et al. (2020) conducted a cohort in Pregnancy complications (n=290). Prothrombin G20210A mutation vs. Wild G20210G genotype was evaluated on Pregnancy complications (RR 2.3, 95% CI 1.7-3.1, p=<0.0001). The prothrombin G20210A mutation increased the risk of pregnancy complications compared to wild-type controls.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: